| Literature DB >> 36180657 |
Linlin Wang1,2, Ying Luo1, Xiaolin Li3, Yixian Li1, Yu Xia1, Tingyan He1, Yanyan Huang1, Yongbin Xu1, Zhi Yang1, Jiayun Ling1, Ruohang Weng1, Xiaona Zhu1, Zhongxiang Qi2, Jun Yang4.
Abstract
PURPOSE: Talaromyces marneffei (TM) is an opportunistic fungus leading to multi-organ damages and poor prognosis in immunocompromised individuals. TM infections in children are rare and our knowledge to TM infection is insufficient. To investigate the clinical characteristics of TM-infected children and to explore the underlying mechanisms for host against TM, we analysed TM-infected patients diagnosed in our hospital.Entities:
Keywords: Children; Gene mutations; Inborn errors of immunity; Primary immunodeficiency diseases; Talaromyces marneffei
Year: 2022 PMID: 36180657 PMCID: PMC9524311 DOI: 10.1007/s11046-022-00659-0
Source DB: PubMed Journal: Mycopathologia ISSN: 0301-486X Impact factor: 3.785
Clinical features of the 8 patients with TM infection
| Patients | Gender | TM Onset age | Medical history | Symptoms/signs | Concurrent infections | Genetic | Outcome |
|---|---|---|---|---|---|---|---|
| P1 | F | 7y11m | 1y3m: thrush, diarrhea, severe pneumonia, disseminated tuberculosis | Weight loss, fever, skin lesions, CMC, pneumonia, hepatosplenomegaly, lymphadenopathy, anemia | EBV, rotavirus | (WES) | Improved |
| P2 | M | 1y5m | 1y3m: lymphatic tuberculosis | Weight loss, fever, pneumonia, ARDS, thrush, diarrhea, hepatomegaly, hepatic failure, pancytopenia | CMV, | (IEI panel) | Death |
| P3 | M | 1y1m | 5 m:axillary abscess; 6 m: severe pneumonia, ARDS, eosinophilia, CMV infections | Weight loss, fever, pneumonia, abdominal distension, diarrhea, hematochezia, jaundice, hypothyroidism, hapatosplenomegaly, lymphadenopathy, portal hypertension, cavernous transformation of the portal vein anemia | CMV, | (IEI panel) | Death |
| P4 | F | 2y5m | – | Weight loss, fever, disturbance of consciousness, intracranial infection, cerebral infarction, cerebral hernia, pneumonia, respiratory failure, lymphadenopathy, skin lesions, anemia | (IEI panel) | Death | |
| P5 | M | 8 m | 3 m: PJP Family history: One brother died from TM infection at 6 m | Fever, pneumonia, rash, edema, hematuresis, diarrhea, hepatosplenomegaly, anemia, thrombocytopenia | Rhinovirus | (IEI panel) | Death |
| P6 | M | 4 m | alpha thalassaemia | Weight loss, fever, pneumonia, peritonitis, hepatosplenomegaly, pancytopenia, HLH, MODS, | Disseminated tuberculosis, | (WES) | Death |
| P7 | M | 4y7m | – | Weight loss, fever, lymphadenopathy, hepatosplenomegaly | – | (WES) | Improved |
| P8 | M | 8y6m | – | Weight loss, fever, pneumonia, osteolytic lesions, lymphadenopathy, hepatosplenomegaly, lymphopenia, CMC | Rhinovirus, S. | (WES) | Improved |
TM T. marneffei, F female, M male, CMV cytomegalovirus, EBV Epstein-Barr virus, PJP pneumocystis jiroveci pneumonia, CMC chronic mucocutaneous candidiasis, ARDS acute respiratory distress syndrome, HLH hemophagocytic lymphohistiocytosis, MODS multiple organ dysfunction syndrome, WES whole exome sequencing, IEI inborn errors of immunity
Fig. 1Flow cytometric analysis of immunological functions in patients with T.marneffei infections. a Proportions of CD3 + CD8-IL-17A + T cells following stimulation with PMA and ionomycin were reduced in P1 and P8. b Percentages of CD19 + IgD-CD27 + memory B cells were decreased in P3 and P4. c The expression of CD40 ligand in CD4+ T cells stimulated by PMA and ionomycin was dramatically reduced in P3
Treatments of IEI patients with TM infections
| Patients | Antifungal | Anti-TB | Other treatments |
|---|---|---|---|
| P1 | VCZ, AmB, ITZ, FCZ | INH, RFP, PZA, LNZ | IVIG |
| P2 | VCZ, AmB | INH, RFP | CoSMZ, GCV, IVIG |
| P3 | VCZ, ITZ, AmB | – | CoSMZ, GCV, IVIG |
| P4 | VCZ, MCFG, AmB, ITZ | INH, RFP, PZA | ACV, DXM, IVIG |
| P5 | VCZ, AmB, ITZ | – | CoSMZ, IVIG |
| P6 | VCZ | INH, RFP, PZA, LNZ | MP, VP-16, CoSMZ, IVIG |
| P7 | AmB, ITZ | – | – |
| P8 | VCZ, ITZ | – | – |
IEI inborn errors of immunity, TM T. marneffei, AmB amphotericin B, VCZ voriconazole, ITZ itraconazole, FCZ fluconazole, MCFG micafungin, INH isoniazid, RFP rifampicin, PZA pyrazinamide, LNZ linezolid, CoSMZ compound sulfamethoxazole and trimethoprim, AZM azithromycin, GCV ganciclovir, ACV acyclovir, DXM dexamethasone, MP methylprednisolone, VP-16 etoposide, IVIG intravenous immunoglobulin
Reported inborn errors of immunity in HIV-negative children with T. marneffei infection
| Patient number | Geneticdefect | Inheritance | Nucleotide change | Amino acid change | Mutation type | Outcome | References |
|---|---|---|---|---|---|---|---|
| P1 | AD GOF | c.1053G > T | p.L351F | Missense | Improved | This study | |
| P2 | AR | (1) c.730delG (2) c.202T > A | (1) p.E244KfsX67 (2) p.Y68N | Compound heterozygous mutations | Dead | This study | |
| P3 | XL | – | – | Large fragment deletion including exon1-5 | Dead | This study | |
| P4 | AD LOF | c.115G > A | p.E39K | Missense | Dead | This study | |
| P5 | XL | c.464G > A | p.W155X | Nonsense | Dead | This study | |
| P6 | XL | c.464G > A | p.W155X | Nonsense | Dead | This study | |
| P7 | AD GOF | c.193G > A | p.D65N | Missense | Improved | This study | |
| P8 | AD GOF | c.1170G > A | p.M390I | Missense | Improved | This study | |
| P9 | AD GOF | c.800C > T | p.A267V | Missense | Improved | [ | |
| P10 | AD GOF | c.821G > A | p.R274Q | Missense | Improved | [ | |
P11 (adult) | AD GOF | c.859 T > A | p.Y287N | Missense | Improved | [ | |
| P12 | AD GOF | c.863C > T | p.T288I | Missense | Improved | [ | |
| P13 | AD GOF | c.1053G > T | p.L351F | Missense | Improved | [ | |
| P14 | AD GOF | c.1074G > T | p.L358F | Missense | Dead | [ | |
| P15 | AD GOF | c.1170G > A | p.M390I | Missense | Improved | [ | |
| P16 | AD GOF | c.193G > A | p.D65N | Missense | Improved | [ | |
| P17 | AD LOF | c.1679_1681del | Not stated | Deletion | Improved | [ | |
| P18 | AD LOF | c.1593A > T | Not stated | Missense | Improved | [ | |
| P19 | AD LOF | c.1593A > T | p.K531N | Missense | Improved | [ | |
P20 (adult) | AD LOF | c.92G > A | p.R31Q | Missense | Improved | [ | |
| P21 | AD LOF | c.1121A > G | p.D374G | Missense | Improved | [ | |
| P22 | AD LOF | c.1673G > A | p. G558D | Missense | Improved | [ | |
| P23 | XL | c.424_436del | Not stated | Deletion | Improved | [ | |
| P24 | XL | > 132 kb | Not stated | Large fragment deletion | Improved | [ | |
| P25 | XL | c.1978 + 1G > A | Not stated | Splicing error | Improved | [ | |
| P26 | XL | c.598A > T | Not stated | Missense | Improved | [ | |
| P27 | XL | g.IVS1-3 T > G (c.157insAG) | p.I53RfsX2 | Splicing error | Dead | [ | |
| P28 | XL | g.IVS1 + 1G > A (c.75-156del82bp) | p.M25IfsX26 | Splicing error | Improved | [ | |
| P29 | XL | g.IVS3 + 1G > A (exon3 missing) | – | Splicing error | Improved | [ | |
| P30 | XL | g.IVS1-1G > A (c.158-161delTAGA) | p.I53KfsX13 | Splicing error | Lost to follow-up | [ | |
| P31 | XL | g.IVS4 + 1G > C (exon4 missing) | p.L116-136del | Splicing error | Improved | [ | |
| P32 | XL | – | – | Large fragment deletion including exon4-5 | Improved | [ | |
| P33 | XL | g.IVS1 + 1G > A | p.M25IfsX26 | Splicing error | Improved | [ | |
| P34 | XL | c.185G > A | Not stated | Nonsense | Dead | [ | |
| P35 | AR | (1) c.440 T > C (2) c.586A > G | (1)p.L147P (2)p.K196E | Compound heterozygous mutations | Dead | [ | |
| P36 | AR | (1) c.1118G > C (2) c.610C > T | (1)p.R373P (2)p.R204C | Compound heterozygous mutations | Improved | [ | |
| P37 | AR | c.182dupT | p.V61fsX69 | Insertion | Dead | [ | |
| P38 | AR | c.182dupT | p.V61fsX69 | Insertion | Improved | [ | |
| P39 | AR | c.400_401insAGC | p.Q135_R136insQ | Insertion | Improved | [ | |
| P40 | AD | c.2540dupT | – | Insertion | Improved | [ |
HIV human immunodeficiency virus, AD autosomal dominant, AR autosomal recessive, XL X-linked, GOF gain-of-function